Early-onset parkinsonism in a pedigree with phosphoglycerate kinase deficiency and a heterozygous carrier: do PGK-1 mutations contribute to vulnerability to parkinsonism?

<p dir="ltr">Phosphoglycerate kinase 1 (PGK-1) is a glycolytic enzyme encoded by PGK-1, which maps to the X chromosome. PGK-1 deficiency causes X-linked recessive hereditary chronic hemolytic anemia, myopathy, and neurological disorders due to insufficient ATP regeneration. Early-ons...

Full description

Saved in:
Bibliographic Details
Main Author: Satoshi Sakaue (19725322) (author)
Other Authors: Takashi Kasai (718121) (author), Ikuko Mizuta (6578597) (author), Masaya Suematsu (12006506) (author), Shinya Osone (769429) (author), Yumiko Azuma (318823) (author), Toshihiko Imamura (769424) (author), Takahiko Tokuda (105837) (author), Hitoshi Kanno (5439200) (author), Omar M. A. El-Agnaf (8809331) (author), Masafumi Morimoto (4633492) (author), Masanori Nakagawa (105840) (author), Hajime Hosoi (259258) (author), Toshiki Mizuno (105838) (author)
Published: 2017
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<p dir="ltr">Phosphoglycerate kinase 1 (PGK-1) is a glycolytic enzyme encoded by PGK-1, which maps to the X chromosome. PGK-1 deficiency causes X-linked recessive hereditary chronic hemolytic anemia, myopathy, and neurological disorders due to insufficient ATP regeneration. Early-onset parkinsonism has occasionally been reported as a neurological complication of this condition. However, heterozygous carriers of PGK-1 deficiency were thought to be neurologically asymptomatic. Here, we report a boy with PGK-1 deficiency and his mother, a carrier of a heterozygous mutation in PGK-1, both of whom presented with early-onset parkinsonism. The boy developed parkinsonism at 9 years of age. His parkinsonism partially responded to levodopa treatment. 123l-metaiodobenzylguanidine (MIBG) uptake was normal. His mother, who exhibited normal PGK-1 activity in erythrocytes, developed parkinsonism at 36 years of age. Her symptoms were undistinguishable from those of Parkinson’s disease (PD), despite her normal uptake of MIBG. Neither a point mutation in nor multiplication of SNCA was found. Additionally, hotspots of LRRK2 and GBA were not mutated. To our knowledge, this report provides the first description of parkinsonism in a carrier of PGK-1 deficiency. Interestingly, PGK-1 is located within the confirmed susceptibility locus for PD known as PARK12. These observations suggest that PGK-1 mutations confer susceptibility to PD.</p><h2>Other Information</h2><p dir="ltr">Published in: npj Parkinson's Disease<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1038/s41531-017-0014-4" target="_blank">https://dx.doi.org/10.1038/s41531-017-0014-4</a></p>